EMA Discusses Disruptive Impact Of ‘Bad Submission Planning’ By Pharma

 
• By Vibha Sharma

The European Medicines Agency has shared real-life examples of how poor planning by companies results in repeated delays to their planned marketing authorization applications, which in turn causes a drain on resources.

Businessman with aspiration of becoming superhero
Companies Should Avoid Being Overly Optimistic When Deciding On Their Planned Filing Date (Shutterstock)

More from Pathways & Standards

More from Agency Leadership